Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269… Read more
Market Cap & Net Worth: Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192)
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (SHG:688192) has a market capitalization of $3.05 Billion (CN¥22.41 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #6843 globally and #1099 in its home market, demonstrating a -0.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's stock price CN¥48.23 by its total outstanding shares 464633342 (464.63 Million).
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Market Cap History: 2021 to 2026
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows growth from $2.34 Billion to $3.05 Billion (3.83% CAGR).
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.30x
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's market cap is 7.30 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.34 Billion | $10.29 Million | -$669.88 Million | 227.86x | N/A |
| 2023 | $3.03 Billion | $91.29 Million | -$1.11 Billion | 33.19x | N/A |
| 2024 | $2.63 Billion | $359.90 Million | -$845.96 Million | 7.30x | N/A |
Competitor Companies of 688192 by Market Capitalization
Companies near Dizal (Jiangsu) Pharmaceutical Co. Ltd. A in the global market cap rankings as of March 18, 2026.
Key companies related to Dizal (Jiangsu) Pharmaceutical Co. Ltd. A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's market cap moved from $2.34 Billion to $ 3.05 Billion, with a yearly change of 3.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.05 Billion | -16.27% |
| 2025 | CN¥3.65 Billion | +38.90% |
| 2024 | CN¥2.63 Billion | -13.33% |
| 2023 | CN¥3.03 Billion | +21.54% |
| 2022 | CN¥2.49 Billion | +6.38% |
| 2021 | CN¥2.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.05 Billion USD |
| MoneyControl | $3.05 Billion USD |
| MarketWatch | $3.05 Billion USD |
| marketcap.company | $3.05 Billion USD |
| Reuters | $3.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.